Core Viewpoint - The innovative pharmaceutical stocks have shown a rebound, with notable increases in share prices for several companies, driven by recent policy developments and market dynamics [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, reaching HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, reaching HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, reaching HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing consultation for the commercial insurance innovative drug list [1] - The fourth batch of traditional Chinese medicine centralized procurement was launched, and new policies regarding medical devices were introduced in Beijing [1] - The State Council meeting outlined plans to promote provincial-level coordination of basic medical insurance [1] Group 3: Market Insights - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, indicating potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary vacuum in domestic BD outbound transactions, several collaborations with multinational corporations (MNCs) have emerged since Q4, reflecting the recognition of domestic innovative drug companies' R&D capabilities [1] - The strong competitive advantages of China's innovative drug industry, including the capacity of the industry chain, pipeline quantity and quality, and R&D efficiency, are expected to drive long-term industry trends [1]

Core Viewpoint - The Hong Kong innovative drug concept stocks have shown a rebound today, indicating a positive market sentiment towards this sector [1] Company Performance - Gilead Sciences-B (01672.HK) increased by 10.26%, reaching HKD 13.11 [1] - CanSino Biologics (09926.HK) rose by 4.15%, trading at HKD 123.1 [1] - Zai Lab (09688.HK) saw a gain of 3.36%, with a price of HKD 15.69 [1] - Ascletis Pharma (02096.HK) grew by 2.9%, priced at HKD 13.48 [1]

Core Viewpoint - The innovative drug sector is experiencing a rebound, with notable stock price increases for several companies following recent policy developments in China's healthcare system [1] Group 1: Stock Performance - Gilead Sciences-B (01672) increased by 10.26%, reaching HKD 13.11 [1] - Kangfang Biotech (09926) rose by 4.15%, priced at HKD 123.1 [1] - Zai Lab (09688) saw a 3.36% increase, trading at HKD 15.69 [1] - Xiansheng Pharmaceutical (02096) grew by 2.9%, now at HKD 13.48 [1] Group 2: Policy Developments - In November, the National Healthcare Security Administration initiated negotiations for the 2025 National Basic Medical Insurance Drug List and the pricing of innovative drugs for commercial insurance [1] - The fourth batch of traditional Chinese medicine procurement has commenced, and new policies regarding medical devices have been introduced in Beijing [1] - The State Council has outlined plans to advance provincial-level coordination of basic medical insurance [1] Group 3: Investment Opportunities - Bohai Securities highlighted the importance of the upcoming release of the new basic medical insurance drug list and the first commercial insurance innovative drug list in early December, suggesting potential investment opportunities in related pharmaceutical companies [1] - Zhongyou Securities noted that despite a temporary lull in domestic BD (business development) transactions, there have been multiple collaborations with multinational corporations (MNCs) since Q4, indicating ongoing interest in domestic innovative drug companies [1] - The purchasing behavior of overseas MNCs is seen as a validation of the innovative research capabilities of domestic companies, reflecting China's strong competitive advantages in the global innovative drug industry [1]

每经AI快讯，12月4日，港股创新药板块午后持续走强，歌礼制药涨超9%，药明生物涨超近5%。 （文章来源：每日经济新闻） ...

Core Viewpoint - The Hong Kong stock market's innovative drug concept stocks are experiencing a continuous rebound, with notable increases in share prices for several companies [1] Group 1: Company Performance - Gilead Sciences-B has seen a rise of over 9% [1] - WuXi Biologics has increased by more than 6% [1] - Other companies such as Rongchang Biopharmaceutical, Innovent Biologics, and I-Mab have also shown upward movement in their stock prices [1]

Group 1 - The Hang Seng Index rose by 0.19%, gaining 48 points to close at 25,809 points, while the Hang Seng Tech Index increased by 0.58% [1] - The trading volume in the Hong Kong stock market reached 92.2 billion HKD in the morning session [1] - Robotics concept stocks led the gains, with several stocks rising over 3%, driven by reports of the Trump administration promoting the robotics industry [1] Group 2 - UBTECH (09880) rose over 3% after announcing a partnership with ZHOS Technology to deploy 10,000 humanoid robots over five years [2] - Hesai Technology (02525) increased by over 6% following the release of its self-developed RISC-V laser radar main control chip, Fermi C500 [2] - InnoCare Pharma (02577) saw a rise of over 4% after forming a strategic partnership with ON Semiconductor to advance the GaN ecosystem [2] - Dazhong Public Utilities (01635) surged over 6% ahead of the listing of Moole Thread, with its subsidiary Deep Venture Capital participating in the investment [2] - Global New Materials International (06616) rose over 5%, with its stock price doubling since the end of October, following an increase in holdings of Seven Color Pearl Coatings [2] - Gilead Sciences-B (01672) increased over 9% after repurchasing 1.3 million shares and announcing a buyback of up to 300 million HKD [2] - Kacos-B (01167) saw a mid-session rise of over 5% after its subsidiary received a 125 million HKD initial payment for a joint therapy featured in The Lancet [2] - Pacific Shipping (02343) rose over 4% as the BDI index reached a nearly two-year high, indicating a turning point for the dry bulk shipping industry [2] - Capital Market Holdings (00204) fell over 40%, with a cumulative decline of over 80% this week, following a significant transfer of shares [2]

Group 1 - The core viewpoint of the articles highlights significant stock movements in the Hong Kong and US markets, driven by company announcements and strategic partnerships [1][2][5][6][7]. Group 2 - Gilead Sciences-B (01672) saw a nearly 9% increase after announcing a share buyback plan, utilizing up to 300 million HKD for repurchases [1]. - OSL Group (00863) rose nearly 2% as it plans to offer compliant digital asset trading services in Europe by Q1 2026 [1]. - Gako Science-B (01167) increased over 5% following a 125 million RMB payment from Haisheng Capital, enhancing its cash reserves for oncology therapy development [1]. - Zhida Technology (02650) surged over 4%, reaching a new high, after signing a sales order exceeding 100 million RMB with Saudi Controls Ltd for a five-year collaboration [2]. - Capital界金控 (00204) fell over 40%, marking a historical low, with a cumulative decline exceeding 80% for the week [2]. - Semiconductor stocks performed well, with Huahong Semiconductor (01347) up 3.18%, Shanghai Fudan (01385) up 2.79%, and SMIC (00981) up 1.86% [2]. - Pacific Shipping (02343) rose nearly 5% as the Baltic Dry Index reached 2845 points, a 9.42% increase, marking the largest rise since October 2025 [3]. - Aoda Holdings (09929) resumed trading with a surge of over 200%, following a major share sale involving 1.5 billion shares at a price of 0.11 HKD per share [4]. - Robotics stocks saw significant gains, with Dechang Motor Holdings (00179) up 9.11% and Sanhua Intelligent Control (02050) up 9.06% [4]. - Ansem Semiconductor (ON.US) rose 11.01% after announcing a strategic partnership with Innosec to advance GaN technology applications [5]. - The Nasdaq Golden Dragon Index fell 1.38%, with notable declines in popular Chinese stocks like Xpeng Motors (XPEV.US) down 4.02% and Alibaba (BABA.US) down 1.89% [5]. - Microchip Technology (MCHP.US) increased by 12.17% after raising its revenue and earnings per share forecasts due to strong booking performance [6]. - Bitcoin-related stocks saw gains, with Iren Ltd (IREN.US) up 6.91% and Coinbase (COIN.US) up 5.19% [6]. - The robotics sector in the US experienced a boost, with Richtech Robotics (RR.US) up 18.54% and iRobot (IRBT.US) up 73.85% amid government support for the industry [7].

值得注意的是，歌礼制药上月发布公告，每月一次新一代胰淀素受体激动剂ASC36和每月一次新一代 GLP-1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国 FDA递交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请。 本文源自：智通财经网 智通财经获悉，歌礼制药-B(01672)早盘涨超10%，截至发稿，涨9.42%，报13.01港元，成交额2929.53 万港元。 消息面上，歌礼制药发布公告，12月3日，公司耗资1592.75万港元回购130.6万股。据悉，歌礼制药今年 10月份公布，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿港元 的资金进行建议股份购回。 ...

Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.19% to 25,809.45 points, the Hang Seng Tech Index up by 0.58%, and the National Enterprises Index rising by 0.38% [8][12]. Technology Sector - The technology sector showed mixed performance, with companies like Xiaomi, Bilibili, and Meituan rising over 2%, while Baidu fell by more than 0.5% [8][12]. Robotics Sector - Robotics stocks strengthened, particularly Sanhua Intelligent Controls, which surged over 9%. The U.S. Secretary of Commerce, Gina Raimondo, indicated strong government support for the robotics industry, with potential executive orders expected next year [3][11]. Semiconductor Sector - The semiconductor sector led the gains, with InnoSilicon rising over 4%. InnoSilicon has entered a strategic partnership with ON Semiconductor to accelerate the application of gallium nitride (GaN) technology, which is expected to generate hundreds of millions in sales over the coming years [12][6]. Innovative Pharmaceuticals - The innovative pharmaceuticals sector showed signs of recovery, with Gilead Sciences rising over 8%. A report from CICC indicated a leading rating for the mainland pharmaceutical industry, predicting a critical turning point by 2025 [12][13].

歌礼制药-B（01672）盘中涨超10%，截至发稿，股价上涨9.76%，现报13.05港元，成交额3508.53万港 元。 歌礼制药发布公告，12月3日，公司耗资1592.75万港元回购130.6万股。据悉，歌礼制药今年10月份公 布，董事会已决定行使购回授权，并根据市况不时于公开市场购回股份，以使用最多3亿港元的资金进 行建议股份购回。 值得注意的是，歌礼制药上月发布公告，每月一次新一代胰淀素受体激动剂ASC36和每月一次新一代 GLP-1R/GIPR双靶点激动剂ASC35复方制剂进入临床开发阶段。歌礼预计将于2026年第二季度向美国 FDA递交ASC36和ASC35复方制剂用于治疗肥胖症的新药临床试验申请。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 客户端 歌礼制药-B（01672）盘中涨超10%，截至发稿，股价上涨9.76%，现报13.05港元，成交额3508.53万港 元。 歌礼制药发布公告，12月3日，公司耗资1592.75万港元回购130.6万股。据悉，歌礼制药今年10月份公 布，董事会已决定行使购 ...